Soligenix Inc. (SNGX) PT Set at $5.00 by Maxim Group

Soligenix Inc. (NASDAQ:SNGX) has been given a $5.00 price objective by equities researchers at Maxim Group in a report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price would indicate a potential upside of 171.74% from the stock’s current price.

Separately, HC Wainwright began coverage on Soligenix in a research report on Monday, July 17th. They set a “buy” rating for the company.

Soligenix (NASDAQ SNGX) traded up 7.6467% on Tuesday, reaching $1.9807. 161,783 shares of the company’s stock were exchanged. The stock’s market capitalization is $11.34 million. Soligenix has a 1-year low of $1.74 and a 1-year high of $5.08. The firm’s 50 day moving average is $2.19 and its 200 day moving average is $2.36.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Friday, August 11th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.09). The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $1.43 million. Soligenix had a negative return on equity of 129.88% and a negative net margin of 86.15%. Analysts expect that Soligenix will post ($1.48) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/10/31/soligenix-inc-sngx-pt-set-at-5-00-by-maxim-group.html.

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

What are top analysts saying about Soligenix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Soligenix Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit